| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 30 | IT 5 | 98.67 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 383 | IT 18 | 99.10 |
| Renal cell carcinoma treatment | Lifetime | 191 | IT 10 | 99.01 |
| Testicular diseases and treatments | Lifetime | 84 | IT 6 | 98.79 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 249 | IT 9 | 98.32 |
| Prostate Cancer Treatment and Research | Lifetime | 313 | IT 7 | 99.05 |
| Neuroblastoma Research and Treatments | Lifetime | 415 | IT 41 | 97.77 |
| Cancer Diagnosis and Treatment | Lifetime | 570 | IT 35 | 97.23 |
| Cancer, Lipids, and Metabolism | Lifetime | 607 | IT 18 | 97.80 |
| Cancer Cells and Metastasis | Lifetime | 764 | IT 29 | 97.06 |
| Economic and Financial Impacts of Cancer | Lifetime | 277 | IT 7 | 96.82 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 625 | IT 41 | 97.64 |
| PARP inhibition in cancer therapy | Lifetime | 307 | IT 14 | 96.17 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 844 | IT 48 | 97.50 |
| Multiple and Secondary Primary Cancers | Lifetime | 787 | IT 55 | 92.90 |
| Advanced Breast Cancer Therapies | Lifetime | 950 | IT 80 | 92.73 |
| Gestational Trophoblastic Disease Studies | Lifetime | 853 | IT 43 | 80.40 |
| Prostate Cancer Treatment and Research | 2021-2025 | 33 | IT 3 | 99.60 |
| Renal cell carcinoma treatment | 2021-2025 | 47 | IT 11 | 99.08 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 57 | IT 2 | 98.23 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 265 | IT 22 | 98.97 |
| PARP inhibition in cancer therapy | 2021-2025 | 39 | IT 5 | 98.62 |
| Cancer Genomics and Diagnostics | 2021-2025 | 226 | IT 19 | 98.26 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 109 | IT 18 | 98.50 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 108 | IT 5 | 97.17 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 197 | IT 36 | 97.48 |
| Testicular diseases and treatments | 2021-2025 | 60 | IT 5 | 93.73 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 460 | IT 70 | 93.64 |
| Advanced Breast Cancer Therapies | 2021-2025 | 337 | IT 36 | 93.94 |
| Cancer Diagnosis and Treatment | 2021-2025 | 382 | IT 32 | 84.03 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 797 | IT 45 | 89.66 |
| Renal and related cancers | 2021-2025 | 563 | IT 58 | 86.55 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 403 | IT 16 | 83.12 |
| Urinary and Genital Oncology Studies | 2021-2025 | 692 | IT 89 | 85.03 |
| Hormonal and reproductive studies | 2021-2025 | 598 | IT 95 | 80.99 |
| Bone health and treatments | 2021-2025 | 781 | IT 79 | 74.88 |
| Genital Health and Disease | 2021-2025 | 799 | IT 89 | 73.16 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 708 | IT 51 | 71.85 |
